港股詳情

本頁面由Tiger Fintech (Singapore) Pte. Ltd.提供服務

百奧賽圖-B

23.800

0.000

成交量：23.05萬

成交額：544.85萬

市值：95.06億

市盈率：258.94

高：24.200

開：23.800

低：23.080

收：23.800

52周最高：31.340

52周最低：5.600

股本：3.99億

香港流通股本：1.11億

量比：0.72

換手率：0.21%

股息：- -

股息率：- -

每股收益(LYR):0.092

淨資產收益率：16.11%

總資產收益率：6.20%

市淨率：9.77

市盈率(LYR):258.94

市銷率: 7.32

資料載入中...

總覽公司新聞公告

百奧賽圖合作伙伴IDEAYA舉辦十週年研發日，攜手推進雙抗ADC聯合治療新篇章

基本面沒變，港股混得不咋地的百奧賽圖，能混好A股嗎？儘管鉅虧32.5億以上，沈月雷2024年年薪42

百奧賽圖IPO:公司基本信息速覽

览富财经网

生物醫藥B類股午後拉昇，百奧賽圖漲超11%，潤邁德漲超8%，加科思漲超5%

老虎资讯综合

百奧賽圖(02315)技術平台頻結碩果連籤默克、Tubulis等推進國際化合作

港股異動 | 百奧賽圖漲超10%，科創版IPO即將接受審議，月初與默克達成抗體授權合作

募資11.85億，百奧賽圖衝刺科創板！

百奧賽圖再闖科創板：專職研發僅剩5人，實控人負債問題待解

港股異動 | 百奧賽圖-B(02135)午後漲超7% 再與Tubulis達成許可交易公司月初與默克達成合作

百奧賽圖-B盤中異動下午盤股價大漲5.17%

百奧賽圖：月內兩次授權，上半年營收增超51%

百奧賽圖宣佈ADC創新企業Tubulis簽署單一抗體全球獨家許可協議

百奧賽圖宣佈Tubulis簽署抗體許可協議以推進ADC療法開發

生物醫藥B類股多數上漲，三葉草生物漲超24%，百奧賽圖漲超12%

老虎资讯综合

港股異動 | 百奧賽圖-B(02315)漲超10% 與默克簽署抗體選擇權評估協議推進抗體偶聯脂質遞送解決方案

百奧賽圖-B09月12日主力淨流出95.2萬元散户資金買入

百奧賽圖-B盤中異動早盤股價大跌7.13%

百奧賽圖-B09月08日主力淨流入187.2萬元散户資金拋售

百奧賽圖與Merck達成合作協議，共同推進抗體偶聯脂質遞送解決方案

百奧賽圖與默克簽署協議，推進抗體偶聯脂質遞送解決方案

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/02315/news?page=3"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"02315","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"02315\",,,,,undefined,":{"symbol":"02315","market":"HK","secType":"STK","nameCN":"百奧賽圖-B","latestPrice":23.8,"timestamp":1761034089105,"preClose":23.8,"halted":0,"volume":230500,"delay":0,"floatShares":110781920,"shares":399398420,"eps":0.09191389597631022,"marketStatus":"未開盤","change":0,"latestTime":"10-21 16:08:09","open":23.8,"high":24.2,"low":23.08,"amount":5448520,"amplitude":0.047059,"askPrice":23.9,"askSize":500,"bidPrice":23.8,"bidSize":1000,"shortable":0,"etf":0,"ttmEps":0.3632177069476074,"tradingStatus":0,"nextMarketStatus":{"tag":"開盤","tradingStatus":2,"beginTime":1761096600000},"marketStatusCode":0,"adr":0,"listingDate":1661961600000,"exchange":"SEHK","adjPreClose":23.8,"openAndCloseTimeList":[[1761010200000,1761019200000],[1761022800000,1761033600000]],"volumeRatio":0.7183473709508942,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"02315\",,,,,undefined,":{"symbol":"02315","floatShares":110781920,"roa":"6.20%","roe":"16.11%","lyrEps":0.091914,"volumeRatio":0.7183473709508942,"shares":399398420,"dividePrice":0,"high":24.2,"amplitude":0.047059,"preClose":23.8,"low":23.08,"week52Low":5.6,"pbRate":"9.77","psRate":"7.32","week52High":31.34,"institutionHeld":0,"latestPrice":23.8,"committee":0.333333,"eps":0.09191389597631022,"divideRate":0,"volume":230500,"delay":0,"ttmEps":0.3632177069476074,"open":23.8,"prevYearClose":8.5,"prevWeekClose":22.76,"prevMonthClose":28.48,"prevQuarterClose":28.48,"fiveDayClose":22.66,"twentyDayClose":27.5,"sixtyDayClose":20.8},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/02315\",params:#limit:5,,,undefined,":[{"date":"2025-08-28","symbol":"02315","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1756344600000,"name":null,"time":"","dateTimestamp":1756310400000,"actualEps":null},{"date":"2025-03-26","symbol":"02315","type":"earning","reportTimeType":"post","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1742952600000,"name":null,"time":"盤後","dateTimestamp":1742918400000,"actualEps":null},{"market":"HK","date":"2024-08-28","symbol":"02315","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"盤後","type":"earning","dateTimestamp":1724774400000,"reportTimeType":"post","actualEps":null},{"date":"2024-03-27","symbol":"02315","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1711503000000,"name":null,"time":"","dateTimestamp":1711468800000,"actualEps":null},{"date":"2023-08-28","symbol":"02315","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1693186200000,"name":null,"time":"","dateTimestamp":1693152000000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"02315\",market:\"HK\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"02315\",market:\"HK\",delay:false,,,undefined,":{"strongBuy":1,"buy":0,"hold":0,"sell":0,"strongSell":0,"meanLabel":"STRONG BUY","meanPercent":1,"analysts":1,"updateTime":1743436800000},"@#url:\"https://hq.skytigris.cn/hkstock/value_analysis/stock/02315\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"02315","date":"2025-10-20","current":65.527646,"percent":0.828794,"low":-25.760101,"twenty":-15.119968,"median":-9.315346,"eighty":-5.897815,"high":292.060693,"avg":21.342254,"sd":76.405971,"marketCap":9505682396},"quantilePoints":[{"date":"2022-09-02","current":-17.320141,"twenty":-17.183465,"median":-16.97845,"eighty":-16.773436,"marketCap":10750256182},{"date":"2022-09-09","current":-16.423987,"twenty":-16.725792,"median":-16.549247,"eighty":-16.380597,"marketCap":10155223552},{"date":"2022-09-16","current":-16.318147,"twenty":-16.63676,"median":-16.36975,"eighty":-16.316556,"marketCap":9996548184},{"date":"2022-09-23","current":-16.637534,"twenty":-16.675139,"median":-16.58177,"eighty":-16.318147,"marketCap":9996548184},{"date":"2022-09-30","current":-16.676297,"twenty":-16.685959,"median":-16.63676,"eighty":-16.318147,"marketCap":10464238604},{"date":"2022-10-07","current":-16.709082,"twenty":-16.759103,"median":-16.644605,"eighty":-16.32635,"marketCap":10484208525},{"date":"2022-10-14","current":-17.016883,"twenty":-16.759103,"median":-16.64107,"eighty":-16.343742,"marketCap":10564088209},{"date":"2022-10-21","current":-17.166611,"twenty":-17.031627,"median":-16.675139,"eighty":-16.354867,"marketCap":10584058130},{"date":"2022-10-28","current":-16.904053,"twenty":-17.031627,"median":-16.675441,"eighty":-16.36536,"marketCap":10404328841},{"date":"2022-11-04","current":-16.612618,"twenty":-17.082341,"median":-16.676297,"eighty":-16.369306,"marketCap":10324449157},{"date":"2022-11-11","current":-16.306635,"twenty":-17.029879,"median":-16.67602,"eighty":-16.36536,"marketCap":10224599552},{"date":"2022-11-18","current":-16.746191,"twenty":-17.082341,"median":-16.685959,"eighty":-16.369306,"marketCap":10464238604},{"date":"2022-11-25","current":-16.976752,"twenty":-17.082341,"median":-16.684366,"eighty":-16.41314,"marketCap":10524148367},{"date":"2022-12-02","current":-16.467053,"twenty":-17.08023,"median":-16.682773,"eighty":-16.455087,"marketCap":10384358920},{"date":"2022-12-09","current":-16.284129,"twenty":-17.029868,"median":-16.675441,"eighty":-16.360668,"marketCap":10364388999},{"date":"2022-12-16","current":-16.102056,"twenty":-17.016962,"median":-16.650632,"eighty":-16.338699,"marketCap":10224599552},{"date":"2022-12-23","current":-16.065604,"twenty":-16.984778,"median":-16.637147,"eighty":-16.314572,"marketCap":10204629631},{"date":"2022-12-30","current":-15.934887,"twenty":-16.966494,"median":-16.614292,"eighty":-16.270012,"marketCap":10244569473},{"date":"2023-01-06","current":-15.64986,"twenty":-16.949062,"median":-16.590059,"eighty":-16.212217,"marketCap":10164689789},{"date":"2023-01-13","current":-15.537191,"twenty":-16.938757,"median":-16.549025,"eighty":-16.179981,"marketCap":10284509315},{"date":"2023-01-20","current":-15.580379,"twenty":-16.925026,"median":-16.534664,"eighty":-16.156179,"marketCap":10224599552},{"date":"2023-01-27","current":-15.546768,"twenty":-16.914539,"median":-16.533948,"eighty":-16.10098,"marketCap":10204629631},{"date":"2023-02-03","current":-15.436408,"twenty":-16.898489,"median":-16.443424,"eighty":-15.899534,"marketCap":10184659710},{"date":"2023-02-10","current":-15.407922,"twenty":-16.85946,"median":-16.367528,"eighty":-15.72674,"marketCap":10104780026},{"date":"2023-02-17","current":-15.462828,"twenty":-16.826005,"median":-16.357582,"eighty":-15.576487,"marketCap":10044870263},{"date":"2023-02-24","current":-15.747577,"twenty":-16.809749,"median":-16.341273,"eighty":-15.581234,"marketCap":10104780026},{"date":"2023-03-03","current":-16.543432,"twenty":-16.800921,"median":-16.334837,"eighty":-15.597252,"marketCap":10683907735},{"date":"2023-03-10","current":-15.544967,"twenty":-15.579303,"median":-15.560593,"eighty":-15.545027,"marketCap":9964990579},{"date":"2023-03-17","current":-15.303442,"twenty":-16.772422,"median":-16.316556,"eighty":-15.545905,"marketCap":9905080816},{"date":"2023-03-24","current":-15.373763,"twenty":-16.756627,"median":-16.272365,"eighty":-15.544864,"marketCap":10064840184},{"date":"2023-03-31","current":-14.490947,"twenty":-16.750261,"median":-16.244078,"eighty":-15.503171,"marketCap":9964990579},{"date":"2023-04-06","current":-14.616535,"twenty":-16.74805,"median":-16.201654,"eighty":-15.47105,"marketCap":10044870263},{"date":"2023-04-14","current":-14.718236,"twenty":-16.746563,"median":-16.189978,"eighty":-15.435882,"marketCap":10124749947},{"date":"2023-04-21","current":-14.522496,"twenty":-16.716504,"median":-16.166943,"eighty":-15.404922,"marketCap":9984960500},{"date":"2023-04-28","current":-14.543652,"twenty":-16.690584,"median":-16.159298,"eighty":-15.375204,"marketCap":9925050737},{"date":"2023-05-05","current":-14.549057,"twenty":-16.684047,"median":-16.100712,"eighty":-15.342097,"marketCap":9945020658},{"date":"2023-05-12","current":-14.620521,"twenty":-16.678887,"median":-16.039544,"eighty":-15.333905,"marketCap":9925050737},{"date":"2023-05-19","current":-14.943491,"twenty":-16.675965,"median":-15.890696,"eighty":-15.23178,"marketCap":9725351527},{"date":"2023-05-25","current":-14.912803,"twenty":-16.675501,"median":-15.809962,"eighty":-15.067549,"marketCap":9665441764},{"date":"2023-06-02","current":-14.437965,"twenty":-16.668929,"median":-15.747577,"eighty":-14.987375,"marketCap":9325953107},{"date":"2023-06-09","current":-14.613629,"twenty":-16.656022,"median":-15.667464,"eighty":-14.759824,"marketCap":9425802712},{"date":"2023-06-16","current":-13.688431,"twenty":-16.648221,"median":-15.639948,"eighty":-14.693346,"marketCap":8786765240},{"date":"2023-06-23","current":-13.012764,"twenty":-16.643191,"median":-15.607551,"eighty":-14.659979,"marketCap":8307487136},{"date":"2023-06-30","current":-13.257814,"twenty":-16.637379,"median":-15.582942,"eighty":-14.61421,"marketCap":8387366820},{"date":"2023-07-07","current":-12.682797,"twenty":-16.632266,"median":-15.576118,"eighty":-14.550185,"marketCap":8007938321},{"date":"2023-07-14","current":-12.819193,"twenty":-16.613957,"median":-15.551683,"eighty":-14.529885,"marketCap":8207637531},{"date":"2023-07-21","current":-12.973057,"twenty":-16.608106,"median":-15.545068,"eighty":-14.516129,"marketCap":8267547294},{"date":"2023-07-28","current":-12.535237,"twenty":-16.582609,"median":-15.540993,"eighty":-14.488236,"marketCap":7979980431},{"date":"2023-08-04","current":-11.938194,"twenty":-16.552097,"median":-15.522734,"eighty":-14.412097,"marketCap":7612533885},{"date":"2023-08-11","current":-10.431222,"twenty":-16.549158,"median":-15.479965,"eighty":-14.353579,"marketCap":6614037835},{"date":"2023-08-18","current":-9.656286,"twenty":-16.54773,"median":-15.439162,"eighty":-14.141185,"marketCap":6078843952},{"date":"2023-08-25","current":-10.146146,"twenty":-16.543346,"median":-15.430512,"eighty":-13.53248,"marketCap":6390374720},{"date":"2023-09-01","current":-12.99564,"twenty":-16.541336,"median":-15.407922,"eighty":-13.291047,"marketCap":7293015149},{"date":"2023-09-08","current":-12.315048,"twenty":-16.534521,"median":-15.387742,"eighty":-12.99529,"marketCap":6829712982},{"date":"2023-09-15","current":-10.219312,"twenty":-16.520569,"median":-15.373763,"eighty":-12.96537,"marketCap":5711397406},{"date":"2023-09-22","current":-10.063213,"twenty":-16.466215,"median":-15.341727,"eighty":-12.868104,"marketCap":5599565848},{"date":"2023-09-29","current":-11.178127,"twenty":-16.455087,"median":-15.334187,"eighty":-12.79424,"marketCap":6230615352},{"date":"2023-10-06","current":-9.993446,"twenty":-16.423987,"median":-15.333905,"eighty":-12.692866,"marketCap":5567613974},{"date":"2023-10-13","current":-9.290433,"twenty":-16.36975,"median":-15.303888,"eighty":-12.547785,"marketCap":5168215554},{"date":"2023-10-20","current":-8.010443,"twenty":-16.367528,"median":-15.102694,"eighty":-12.48935,"marketCap":4449298398},{"date":"2023-10-27","current":-8.488672,"twenty":-16.362478,"median":-15.063511,"eighty":-12.292711,"marketCap":4712901356},{"date":"2023-11-03","current":-8.710133,"twenty":-16.359022,"median":-15.056757,"eighty":-12.104621,"marketCap":4848696818},{"date":"2023-11-10","current":-8.898536,"twenty":-16.357046,"median":-14.912803,"eighty":-11.941145,"marketCap":4952540408},{"date":"2023-11-17","current":-8.747876,"twenty":-16.349399,"median":-14.761097,"eighty":-11.58475,"marketCap":4912600566},{"date":"2023-11-24","current":-9.071472,"twenty":-16.342534,"median":-14.718236,"eighty":-10.82373,"marketCap":5136263681},{"date":"2023-12-01","current":-8.640618,"twenty":-16.330975,"median":-14.677453,"eighty":-10.271499,"marketCap":4912600566},{"date":"2023-12-08","current":-7.758741,"twenty":-16.322161,"median":-14.658546,"eighty":-10.157974,"marketCap":4393382620},{"date":"2023-12-15","current":-7.349523,"twenty":-16.318638,"median":-14.616817,"eighty":-10.062883,"marketCap":4185695441},{"date":"2023-12-22","current":-8.126371,"twenty":-16.317676,"median":-14.584545,"eighty":-9.957278,"marketCap":4625033703},{"date":"2023-12-29","current":-8.362487,"twenty":-16.317157,"median":-14.562072,"eighty":-9.871741,"marketCap":4784793071},{"date":"2024-01-05","current":-7.803247,"twenty":-16.314572,"median":-14.547516,"eighty":-9.761569,"marketCap":4433322462},{"date":"2024-01-12","current":-7.461837,"twenty":-16.302134,"median":-14.536365,"eighty":-9.504477,"marketCap":4241611220},{"date":"2024-01-19","current":-7.035876,"twenty":-16.279423,"median":-14.522365,"eighty":-9.33176,"marketCap":3993984200},{"date":"2024-01-26","current":-6.794958,"twenty":-16.258464,"median":-14.515165,"eighty":-9.235745,"marketCap":3842212800},{"date":"2024-02-02","current":-6.280276,"twenty":-16.248749,"median":-14.494808,"eighty":-9.119832,"marketCap":3546657969},{"date":"2024-02-09","current":-6.080594,"twenty":-16.236113,"median":-14.46742,"eighty":-9.04289,"marketCap":3450802348},{"date":"2024-02-16","current":-6.100388,"twenty":-16.212217,"median":-14.448798,"eighty":-8.990936,"marketCap":3462784301},{"date":"2024-02-23","current":-5.580985,"twenty":-16.200095,"median":-14.377271,"eighty":-8.779882,"marketCap":3151253533},{"date":"2024-03-01","current":-6.821664,"twenty":-16.194567,"median":-14.359409,"eighty":-8.66879,"marketCap":3854194753},{"date":"2024-03-08","current":-6.691446,"twenty":-16.187898,"median":-14.283383,"eighty":-8.531038,"marketCap":3782303037},{"date":"2024-03-15","current":-7.256077,"twenty":-16.179981,"median":-13.930623,"eighty":-8.39945,"marketCap":4097827789},{"date":"2024-03-22","current":-6.151369,"twenty":-16.169224,"median":-13.579636,"eighty":-8.326104,"marketCap":3470772269},{"date":"2024-03-28","current":-8.333872,"twenty":-16.165922,"median":-13.45297,"eighty":-8.269405,"marketCap":3454796333},{"date":"2024-04-05","current":-6.804027,"twenty":-16.165092,"median":-13.428292,"eighty":-8.136639,"marketCap":2819752845},{"date":"2024-04-12","current":-6.357095,"twenty":-16.162416,"median":-13.25289,"eighty":-8.013058,"marketCap":2636029572},{"date":"2024-04-19","current":-7.133743,"twenty":-16.143691,"median":-12.995421,"eighty":-7.920902,"marketCap":2955548308},{"date":"2024-04-26","current":-8.011238,"twenty":-16.101518,"median":-12.982283,"eighty":-7.901825,"marketCap":3315006886},{"date":"2024-05-03","current":-8.4804,"twenty":-16.099367,"median":-12.963448,"eighty":-7.90259,"marketCap":3506718127},{"date":"2024-05-10","current":-9.394996,"twenty":-16.065604,"median":-12.898932,"eighty":-7.913843,"marketCap":3894134595},{"date":"2024-05-17","current":-9.215805,"twenty":-16.044756,"median":-12.867532,"eighty":-7.919339,"marketCap":3814254911},{"date":"2024-05-24","current":-9.246573,"twenty":-15.983649,"median":-12.819193,"eighty":-7.921471,"marketCap":3818248895},{"date":"2024-05-31","current":-8.589796,"twenty":-15.941845,"median":-12.752108,"eighty":-7.961158,"marketCap":3550651953},{"date":"2024-06-07","current":-7.768472,"twenty":-15.864181,"median":-12.691034,"eighty":-7.961158,"marketCap":3207169312},{"date":"2024-06-14","current":-7.814329,"twenty":-15.826431,"median":-12.62649,"eighty":-7.909342,"marketCap":3223145249},{"date":"2024-06-21","current":-7.277623,"twenty":-15.809345,"median":-12.53142,"eighty":-7.79631,"marketCap":2995488150},{"date":"2024-06-28","current":-7.426256,"twenty":-15.789546,"median":-12.48935,"eighty":-7.753383,"marketCap":3055397913},{"date":"2024-07-05","current":-7.495836,"twenty":-15.765827,"median":-12.315048,"eighty":-7.684126,"marketCap":3083355802},{"date":"2024-07-12","current":-7.223066,"twenty":-15.726554,"median":-12.278434,"eighty":-7.629416,"marketCap":2975518229},{"date":"2024-07-19","current":-7.193846,"twenty":-15.685816,"median":-12.106939,"eighty":-7.601973,"marketCap":2963536276},{"date":"2024-07-26","current":-6.703571,"twenty":-15.668373,"median":-11.984006,"eighty":-7.505156,"marketCap":2771825034},{"date":"2024-08-02","current":-6.523845,"twenty":-15.657694,"median":-11.938194,"eighty":-7.459727,"marketCap":2695939335},{"date":"2024-08-09","current":-5.9622,"twenty":-15.645895,"median":-11.636139,"eighty":-7.412301,"marketCap":2480264188},{"date":"2024-08-16","current":-6.420552,"twenty":-15.638291,"median":-11.199705,"eighty":-7.36919,"marketCap":2671975429},{"date":"2024-08-23","current":-6.211949,"twenty":-15.624504,"median":-10.786048,"eighty":-7.29332,"marketCap":2596089730},{"date":"2024-08-30","current":-9.587395,"twenty":-15.607156,"median":-10.431222,"eighty":-7.274264,"marketCap":2568131840},{"date":"2024-09-06","current":-9.344329,"twenty":-15.59757,"median":-10.232292,"eighty":-7.282379,"marketCap":2504228093},{"date":"2024-09-13","current":-8.935525,"twenty":-15.58317,"median":-10.160931,"eighty":-7.29332,"marketCap":2388402551},{"date":"2024-09-20","current":-9.357565,"twenty":-15.581519,"median":-10.098938,"eighty":-7.308194,"marketCap":2516210046},{"date":"2024-09-27","current":-10.320372,"twenty":-15.579527,"median":-10.073832,"eighty":-7.345779,"marketCap":2791794955},{"date":"2024-10-04","current":-14.698364,"twenty":-15.576118,"median":-10.122542,"eighty":-7.349523,"marketCap":3958038342},{"date":"2024-10-10","current":-11.132217,"twenty":-15.571743,"median":-10.161683,"eighty":-7.362761,"marketCap":2979512213},{"date":"2024-10-18","current":-10.459714,"twenty":-15.559408,"median":-10.219312,"eighty":-7.372309,"marketCap":2783806987},{"date":"2024-10-25","current":-10.340316,"twenty":-15.548734,"median":-10.261664,"eighty":-7.392688,"marketCap":2751855113},{"date":"2024-11-01","current":-9.358506,"twenty":-15.545617,"median":-10.176873,"eighty":-7.401158,"marketCap":2492246140},{"date":"2024-11-08","current":-9.082377,"twenty":-15.54512,"median":-10.153538,"eighty":-7.405713,"marketCap":2400384504},{"date":"2024-11-15","current":-9.288588,"twenty":-15.544987,"median":-10.084452,"eighty":-7.417986,"marketCap":2436330362},{"date":"2024-11-22","current":-8.63879,"twenty":-15.54483,"median":-10.062389,"eighty":-7.42517,"marketCap":2264589041},{"date":"2024-11-29","current":-8.902865,"twenty":-15.538712,"median":-9.993446,"eighty":-7.43744,"marketCap":2332486772},{"date":"2024-12-06","current":-9.336462,"twenty":-15.534727,"median":-9.926941,"eighty":-7.454703,"marketCap":2440324346},{"date":"2024-12-13","current":-12.12859,"twenty":-15.525009,"median":-9.993446,"eighty":-7.461134,"marketCap":3167229470},{"date":"2024-12-20","current":-12.949109,"twenty":-15.49665,"median":-10.062389,"eighty":-7.463103,"marketCap":3362934696},{"date":"2024-12-27","current":-13.005336,"twenty":-15.48963,"median":-10.080954,"eighty":-7.464331,"marketCap":3374916649},{"date":"2025-01-03","current":-12.469835,"twenty":-15.485315,"median":-10.098938,"eighty":-7.471726,"marketCap":3239121186},{"date":"2025-01-10","current":-11.884455,"twenty":-15.469406,"median":-10.153538,"eighty":-7.500496,"marketCap":3075367834},{"date":"2025-01-17","current":-11.658965,"twenty":-15.458095,"median":-10.176873,"eighty":-7.522658,"marketCap":3019452055},{"date":"2025-01-24","current":-12.076794,"twenty":-15.438611,"median":-10.261664,"eighty":-7.541025,"marketCap":3147259549},{"date":"2025-01-28","current":-12.004152,"twenty":-15.43751,"median":-10.281809,"eighty":-7.549574,"marketCap":3143265565},{"date":"2025-02-07","current":-11.806203,"twenty":-15.434831,"median":-10.340316,"eighty":-7.578575,"marketCap":3075367834},{"date":"2025-02-14","current":-12.541461,"twenty":-15.429859,"median":-10.454096,"eighty":-7.606855,"marketCap":3259091107},{"date":"2025-02-21","current":-13.329047,"twenty":-15.417717,"median":-10.628219,"eighty":-7.62064,"marketCap":3482754222},{"date":"2025-02-28","current":-14.093919,"twenty":-15.409299,"median":-10.676284,"eighty":-7.632465,"marketCap":3670471479},{"date":"2025-03-07","current":-18.299233,"twenty":-15.417717,"median":-10.848852,"eighty":-7.647988,"marketCap":4784793071},{"date":"2025-03-14","current":-20.796737,"twenty":-15.448628,"median":-11.155172,"eighty":-7.670492,"marketCap":5439806480},{"date":"2025-03-21","current":-24.073812,"twenty":-15.503171,"median":-11.213505,"eighty":-7.682665,"marketCap":6294519099},{"date":"2025-03-28","current":166.890984,"twenty":-15.535343,"median":-11.265741,"eighty":-7.670492,"marketCap":5990976300},{"date":"2025-04-03","current":148.592565,"twenty":-15.52956,"median":-11.188916,"eighty":-7.619299,"marketCap":5335962891},{"date":"2025-04-11","current":137.813994,"twenty":-15.509692,"median":-11.08181,"eighty":-7.526181,"marketCap":4904612597},{"date":"2025-04-17","current":132.251881,"twenty":-15.489879,"median":-10.723244,"eighty":-7.463876,"marketCap":4712901356},{"date":"2025-04-25","current":130.653866,"twenty":-15.488881,"median":-10.665186,"eighty":-7.440236,"marketCap":4664973545},{"date":"2025-05-02","current":155.157263,"twenty":-15.474616,"median":-10.628219,"eighty":-7.405713,"marketCap":5551638038},{"date":"2025-05-09","current":134.566778,"twenty":-15.466117,"median":-10.459714,"eighty":-7.370749,"marketCap":4848696818},{"date":"2025-05-16","current":132.156923,"twenty":-15.448628,"median":-10.385769,"eighty":-7.295224,"marketCap":4800769008},{"date":"2025-05-23","current":176.26836,"twenty":-15.43751,"median":-10.285563,"eighty":-7.262732,"marketCap":6422326593},{"date":"2025-05-30","current":194.268841,"twenty":-15.434831,"median":-10.232292,"eighty":-7.240227,"marketCap":7109291876},{"date":"2025-06-06","current":190.508609,"twenty":-15.429859,"median":-10.162435,"eighty":-7.194033,"marketCap":6989472350},{"date":"2025-06-13","current":242.122352,"twenty":-15.417717,"median":-10.132322,"eighty":-7.161917,"marketCap":8886614845},{"date":"2025-06-20","current":239.872041,"twenty":-15.409299,"median":-10.084452,"eighty":-7.088113,"marketCap":8786765240},{"date":"2025-06-27","current":246.269522,"twenty":-15.398923,"median":-10.062389,"eighty":-7.044514,"marketCap":9046374213},{"date":"2025-07-04","current":250.063256,"twenty":-15.391199,"median":-10.003136,"eighty":-7.007459,"marketCap":9186163660},{"date":"2025-07-11","current":230.181341,"twenty":-15.387916,"median":-9.934047,"eighty":-6.832291,"marketCap":8447276583},{"date":"2025-07-18","current":234.173998,"twenty":-15.382348,"median":-9.913676,"eighty":-6.798586,"marketCap":8587066030},{"date":"2025-07-25","current":225.72884,"twenty":-15.374844,"median":-9.853307,"eighty":-6.692805,"marketCap":8307487136},{"date":"2025-08-01","current":277.909452,"twenty":-15.373763,"median":-9.815898,"eighty":-6.59652,"marketCap":10164689789},{"date":"2025-08-08","current":261.421777,"twenty":-15.361688,"median":-9.735143,"eighty":-6.513228,"marketCap":9585562080},{"date":"2025-08-15","current":268.795789,"twenty":-15.342097,"median":-9.631387,"eighty":-6.417235,"marketCap":9841177068},{"date":"2025-08-22","current":273.580909,"twenty":-15.337645,"median":-9.532105,"eighty":-6.350598,"marketCap":9984960500},{"date":"2025-08-29","current":62.555475,"twenty":-15.334252,"median":-9.483572,"eighty":-6.272638,"marketCap":9042380228},{"date":"2025-09-05","current":69.200112,"twenty":-15.334074,"median":-9.453998,"eighty":-6.171457,"marketCap":9992948468},{"date":"2025-09-12","current":63.498906,"twenty":-15.333905,"median":-9.423977,"eighty":-6.10359,"marketCap":9186163660},{"date":"2025-09-19","current":75.976522,"twenty":-15.323094,"median":-9.37227,"eighty":-6.060838,"marketCap":10983456550},{"date":"2025-09-26","current":79.221129,"twenty":-15.305861,"median":-9.358035,"eighty":-6.019236,"marketCap":11422794812},{"date":"2025-10-03","current":75.937529,"twenty":-15.304156,"median":-9.345758,"eighty":-5.969828,"marketCap":10975468581},{"date":"2025-10-10","current":69.406568,"twenty":-15.303442,"median":-9.33177,"eighty":-5.941754,"marketCap":10016912373},{"date":"2025-10-17","current":63.035254,"twenty":-15.124286,"median":-9.321633,"eighty":-5.913943,"marketCap":9090308039},{"date":"2025-10-20","current":65.957163,"twenty":-15.119968,"median":-9.315346,"eighty":-5.897815,"marketCap":9505682396}],"updateTime":1761068483417},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"02315\",pageSize:20,pageCount:3,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2568925200","title":"百奧賽圖合作伙伴IDEAYA舉辦十週年研發日，攜手推進雙抗ADC聯合治療新篇章","url":"https://stock-news.laohu8.com/highlight/detail?id=2568925200","media":"新浪证券","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2568925200?lang=zh_tw&edition=fundamental","pubTime":"2025-09-19 15:39","pubTimestamp":1758267540,"startTime":"0","endTime":"0","summary":"百奥赛图祝贺合作伙伴IDEAYA Biosciences的十周年研发日在9月8日圆满举行。IDEAYA在会上公布了多项研发进展，其中重点提及了双方合作的B7-H3/PTK7双特异性抗体偶联药物IDE034。IDEAYA预计将在2025年第四季度完成IND申报，预期适应症覆盖肺癌、结直肠癌、头颈鳞癌及卵巢癌患者群体。百奥赛图在双抗ADC研发领域拥有领先优势。随着全球研发趋势逐步迈向多元化与组合化，ADC与小分子药物的联合治疗正日益成为重要方向。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250919153930a436a446&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250919153930a436a446&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","02315"],"gpt_icon":0},{"id":"2568887257","title":"基本面沒變，港股混得不咋地的百奧賽圖，能混好A股嗎？儘管鉅虧32.5億以上，沈月雷2024年年薪42","url":"https://stock-news.laohu8.com/highlight/detail?id=2568887257","media":"中金在线","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2568887257?lang=zh_tw&edition=fundamental","pubTime":"2025-09-19 14:26","pubTimestamp":1758263190,"startTime":"0","endTime":"0","summary":"曾经在港股跌得鼻青脸肿的百奥赛图，如今又要来科创板“吸金”了。9月24日，百奥赛图将迎来科创板上会审议的关键时刻。如今，在港股混得不咋地的百奥赛图，带着几乎同样的基本面转战A股，能混出个名堂吗？根据招股书数据，2021年至2024年，百奥赛图实现营收分别为3.55亿元、5.34亿元、7.17亿元和9.81亿元。更令人担忧的是，研发团队规模从2022年底的627人锐减至2024年6月底的288人，降幅达54%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250919144035a4368a5e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250919144035a4368a5e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["HSTECH","02315","BK1161","HSCEI"],"gpt_icon":1},{"id":"2568252045","title":"百奧賽圖IPO:公司基本信息速覽","url":"https://stock-news.laohu8.com/highlight/detail?id=2568252045","media":"览富财经网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2568252045?lang=zh_tw&edition=fundamental","pubTime":"2025-09-19 14:08","pubTimestamp":1758262103,"startTime":"0","endTime":"0","summary":"百奥赛图将于9月24日接受上交所上市委审核。百奥赛图（北京）医药科技股份有限公司是一家创新药临床前CRO及生物技术公司。此外，百奥常青、百奥常盛、祐和常青、祐和常盛为发行人股权激励平台，截至本招股说明书签署日，合计持有发行人13.1584%股份。该《一致行动协议》在任何一方持有百奥赛图股权期间持续有效。综上，截至招股说明书签署日，沈月雷、倪健合计直接或间接控制发行人 27.0291% 表决权，为百奥赛图共同控股股东、实际控制人。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250919140840979c97ab&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250919140840979c97ab&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02315","09939","BK1161"],"gpt_icon":0},{"id":"1156906272","title":"生物醫藥B類股午後拉昇，百奧賽圖漲超11%，潤邁德漲超8%，加科思漲超5%","url":"https://stock-news.laohu8.com/highlight/detail?id=1156906272","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1156906272?lang=zh_tw&edition=fundamental","pubTime":"2025-09-18 13:27","pubTimestamp":1758173248,"startTime":"0","endTime":"0","summary":"9月18日（周四），港股$生物(000504)$医药B类股午后拉升，$百奥赛图(02315)$涨超11%，润迈德涨超8%，$加科思(01167)$涨超5%，$开拓药业(09939)$涨超5%，和誉、创胜集团、三叶草生物涨超4%","market":"us","thumbnail":"https://static.tigerbbs.com/5caed408891c5ae9176e1a31289a0785","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/5caed408891c5ae9176e1a31289a0785"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"3f74022f06933621fba8da03310c7780","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02297","150131","BK1100","02315"],"gpt_icon":0},{"id":"2568472224","title":"百奧賽圖(02315)技術平台頻結碩果 連籤默克、Tubulis等推進國際化合作","url":"https://stock-news.laohu8.com/highlight/detail?id=2568472224","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2568472224?lang=zh_tw&edition=fundamental","pubTime":"2025-09-18 11:36","pubTimestamp":1758166563,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，近日，百奥赛图公布与默克、Tubulis、IDEAYA的多项合作及研发进展引起市场关注，凸显其在抗体药物研发及创新递送技术领域的平台实力与国际合作成效。此外，百奥赛图近期宣布先后与德国Tubulis及全球领先的科技公司默克达成合作协议。Tubulis拟引进百奥赛图自主开发的全人抗体推进其ADC产品的研发和商业化。百奥赛图将获得一笔首付款，还将有权获得开发、监管及商业化里程碑付款以及个位数净销售额分成。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"1c2e6bc5fe5e88020e64b175354f9941","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1346663.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0234572021.USD","SG9999001176.USD","IE00B2B36J28.USD","LU1116320737.USD","LU1974910355.USD","LU0070302665.USD","SG9999002232.USD","LU1093756325.SGD","LU1035773651.USD","LU0265550946.USD","LU2023250843.SGD","SG9999014559.SGD","MRK","SG9999002224.SGD","SG9999013999.USD","SG9999001440.SGD","IE0009355771.USD","IE00BLSP4239.USD","LU1430594728.SGD","LU1699723380.USD","LU1066051498.USD","LU1069347547.HKD","LU2089984988.USD","IE00BLSP4452.SGD","LU0289739699.SGD","LU0861579265.USD","LU1093756168.USD","LU1162221912.USD","BK4588","LU1989772923.USD","LU1989771016.USD","IE00BJJMRZ35.SGD","IE000M9KFDE8.USD","02315","LU0098860793.USD","LU1571399168.USD","IE00B4R5TH58.HKD","LU1929549753.HKD","LU1585245621.USD","LU0965509101.SGD","LU1116320901.HKD","LU0106261372.USD","LU0266013472.USD","LU1023059063.AUD","LU0203347892.USD","LU2361044949.HKD","LU0211331839.USD","LU2361044865.SGD","IE00BFTCPJ56.SGD","LU1061106388.HKD"],"gpt_icon":0},{"id":"2568444695","title":"港股異動 | 百奧賽圖漲超10%，科創版IPO即將接受審議，月初與默克達成抗體授權合作","url":"https://stock-news.laohu8.com/highlight/detail?id=2568444695","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2568444695?lang=zh_tw&edition=fundamental","pubTime":"2025-09-18 10:01","pubTimestamp":1758160893,"startTime":"0","endTime":"0","summary":"9月18日（周四），$百奥赛图-B$涨超10%，截至发稿，涨10.12%，报27.42港元，成交额1316万港元。消息面上，9月17日，上交所上市审核委员会发布公告，百奥赛图的科创板IPO迎来关键节点，首发事项将于9月24日接受审议。根据协议条款，百奥赛图将提供基于其RenMice平台自主开发的全人抗体，由默克评估将其用于抗体偶联LNP制剂服务的可行性。默克被授予获取选中抗体资产权益的独家选择权，百奥赛图有权获得相应的费用付款及销售分成和再许可分成。","market":"fut","thumbnail":"https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"1c2e6bc5fe5e88020e64b175354f9941","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1346617.html","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4007","LU1116320737.USD","LU2089984988.USD","LU1069347547.HKD","MRK","HSCEI","LU0861579265.USD","IE00BBT3K403.USD","LU1057294990.SGD","IE00BJJMRZ35.SGD","LU1699723380.USD","LU0266013472.USD","IE00BN8TJ469.HKD","BK1161","LU1983299246.USD","SG9999002224.SGD","LU1941712348.USD","IE00BLSP4452.SGD","LU1035773651.USD","LU0070302665.USD","BK4614","LU0238689110.USD","IE0009355771.USD","IE00BFTCPJ56.SGD","LU0098860793.USD","LU2361044949.HKD","LU0211331839.USD","LU1037948541.HKD","LU0058720904.USD","SGXZ57979304.SGD","SG9999014542.SGD","YANG","IE000M9KFDE8.USD","LU1037948897.HKD","LU1989771016.USD","LU0965509010.AUD","LU1989772840.SGD","LU1974910355.USD","02315","LU0965509283.SGD","159982","LU1989772923.USD","LU2023250504.SGD","SG9999002232.USD","IE00BJT1NW94.SGD","BK4559","SG9999001176.SGD","LU1061106388.HKD","LU1571399168.USD"],"gpt_icon":1},{"id":"2568664417","title":"募資11.85億，百奧賽圖衝刺科創板！","url":"https://stock-news.laohu8.com/highlight/detail?id=2568664417","media":"新浪财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2568664417?lang=zh_tw&edition=fundamental","pubTime":"2025-09-17 23:02","pubTimestamp":1758121320,"startTime":"0","endTime":"0","summary":"同日，百奥赛图发布了《首次公开发行股票并在科创板上市招股说明书(上会稿)》。资料显示，百奥赛图成立于2009年，由海归免疫学博士沈月雷创立。近年来，百奥赛图的营收呈现波动增长态势。2025年上半年，百奥赛图业绩表现还算不错。此次科创板IPO，百奥赛图计划募集资金11.85亿元，较最初申报的18.93亿元有所缩水。百奥赛图在港交所上市后，虽获得一定资金，但创新药研发所需的大额投入使其资金压力仍存。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202509180004549798fe43&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202509180004549798fe43&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02315","BK1161"],"gpt_icon":1},{"id":"2567827107","title":"百奧賽圖再闖科創板：專職研發僅剩5人，實控人負債問題待解","url":"https://stock-news.laohu8.com/highlight/detail?id=2567827107","media":"市值观察","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2567827107?lang=zh_tw&edition=fundamental","pubTime":"2025-09-16 20:03","pubTimestamp":1758024182,"startTime":"0","endTime":"0","summary":"通常而言，研发人员薪酬开支是研发费用的重要支出项，2022年2024年百奥赛图的研发人员总数由627人降至337人，专职研发人员由58人下降到仅有5人，剩余均为兼职人员。且百奥赛图总体研发人员占比30.78%，低于可比公司36.61%的平均水平。另外，百奥赛图实际控制人沈月雷夫妇的未到期负债也为其科创板上市蒙上了一层阴影。百奥赛图实控人债务若不能及时展期或偿还，可能面临股权冻结风险，这一风险在招股书中也有提示。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025091620114495318192&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025091620114495318192&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","BK1574","02315","09939","BK1515"],"gpt_icon":0},{"id":"2567176909","title":"港股異動 | 百奧賽圖-B(02135)午後漲超7% 再與Tubulis達成許可交易 公司月初與默克達成合作","url":"https://stock-news.laohu8.com/highlight/detail?id=2567176909","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2567176909?lang=zh_tw&edition=fundamental","pubTime":"2025-09-16 13:52","pubTimestamp":1758001957,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，百奥赛图-B午后涨超7%，截至发稿，涨4.07%，报26.58港元，成交额1673.54万港元。消息面上，9月16日，百奥赛图宣布与德国ADC开发企业Tubulis签署一项抗体许可协议，利用百奥赛图自主开发的RenMice全人抗体开发平台，Tubulis将结合其专有的连接子和有效载荷技术，用于开发创新ADC疗法。百奥赛图董事长、CEO沈月雷表示，Tubulis行使选择权，以及和默克的协议，都彰显了全人抗体平台的国际竞争力和药物转化潜力。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1345693.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0265550946.USD","MRK","LU0861579265.USD","BK4534","LU1929549753.HKD","LU0985320562.USD","LU0122379950.USD","BK4614","BK4588","IE00B4R5TH58.HKD","BK4559","LU1066053197.SGD","LU2106854487.HKD","LU1571399168.USD","LU1037948897.HKD","BK4516","BK4585","02135","LU1291159041.SGD","YANG","LU1941712264.USD","IE0002141913.USD","LU1917777945.USD","LU1989772923.USD","SG9999014575.USD","02315","LU0266013472.USD","LU1934455863.HKD","LU1934455194.USD","LU0965509283.SGD","LU2089984988.USD","LU0265550359.USD","LU0058720904.USD","HSCEI","IE00BSNM7G36.USD","IE00B1BXHZ80.USD","LU2324357040.USD","BK1593","IE00BN8TJ469.HKD","SG9999002224.SGD","LU1023059063.AUD","LU1069347547.HKD","LU1934455277.USD","LU0320765646.SGD","SG9999014542.SGD","LU1066051811.HKD","LU1061106388.HKD","BK4007","LU1093756168.USD"],"gpt_icon":0},{"id":"2568434982","title":"百奧賽圖-B盤中異動 下午盤股價大漲5.17%","url":"https://stock-news.laohu8.com/highlight/detail?id=2568434982","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2568434982?lang=zh_tw&edition=fundamental","pubTime":"2025-09-16 13:00","pubTimestamp":1757998846,"startTime":"0","endTime":"0","summary":"2025年09月16日下午盘13时00分，百奥赛图-B股票出现波动，股价快速上涨5.17%。截至发稿，该股报26.860港元/股，成交量39.95万股，换手率0.36%，振幅5.56%。百奥赛图-B股票所在的生物技术行业中，整体涨幅为21.22%。百奥赛图-B公司简介：北京百奥赛图基因生物技术有限公司是一家主要从事药物开发业务及临床前研究中国公司。消息层面，截至13时00分，《百奥赛图：月内两次授权，上半年营收增超51%》资讯为影响百奥赛图-B的重要信息。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202509161300469530a963&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202509161300469530a963&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","02315"],"gpt_icon":0},{"id":"2567710733","title":"百奧賽圖：月內兩次授權，上半年營收增超51%","url":"https://stock-news.laohu8.com/highlight/detail?id=2567710733","media":"和讯网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2567710733?lang=zh_tw&edition=fundamental","pubTime":"2025-09-16 12:49","pubTimestamp":1757998152,"startTime":"0","endTime":"0","summary":"本月，港股上市的创新型生物技术公司百奥赛图迎来第二个重要授权。该协议源于双方此前的研究合作与选择权协议，百奥赛图将获首付款，还有权获里程碑付款及净销售额分成。一个月内两次重要授权，凸显百奥赛图RenMice平台价值。对外授权是百奥赛图重要收入来源。百奥赛图海外药企合作收入占比近70%，业务覆盖欧美及亚太。上半年营收6.21亿元，同比增超51%，毛利率74.4%，净利润4800万元。百奥赛图持续向海外输出抗体分子，得益于高强度研发投入。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250916125149a4c8c4b7&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250916125149a4c8c4b7&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02315","BK1161"],"gpt_icon":0},{"id":"1111144673","title":"百奧賽圖宣佈ADC創新企業Tubulis簽署單一抗體全球獨家許可協議","url":"https://stock-news.laohu8.com/highlight/detail?id=1111144673","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1111144673?lang=zh_tw&edition=fundamental","pubTime":"2025-09-16 08:01","pubTimestamp":1757980880,"startTime":"0","endTime":"0","summary":"百奥赛图宣布，抗体药物偶联物(ADC)创新企业Tubulis已与其签署了一项关于单一抗体的全球独家许可协议。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02315","BK1161"],"gpt_icon":0},{"id":"2567073591","title":"百奧賽圖宣佈Tubulis簽署抗體許可協議以推進ADC療法開發","url":"https://stock-news.laohu8.com/highlight/detail?id=2567073591","media":"新浪财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2567073591?lang=zh_tw&edition=fundamental","pubTime":"2025-09-16 08:00","pubTimestamp":1757980800,"startTime":"0","endTime":"0","summary":"此次许可协议源自双方此前达成的研究合作与选择权协议，旨在基于百奥赛图的全人抗体发现平台共同探索并推进用于ADC产品开发和商业化的抗体分子。Tubulis将结合其专有的连接子和有效载荷技术，将该抗体用于开发创新ADC疗法，以满足癌症治疗领域未被满足的临床需求。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025091608250295301fa7&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025091608250295301fa7&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02315","BK1161"],"gpt_icon":0},{"id":"1143482169","title":"生物醫藥B類股多數上漲，三葉草生物漲超24%，百奧賽圖漲超12%","url":"https://stock-news.laohu8.com/highlight/detail?id=1143482169","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1143482169?lang=zh_tw&edition=fundamental","pubTime":"2025-09-15 11:17","pubTimestamp":1757906250,"startTime":"0","endTime":"0","summary":"9月15日（周一），$生物(000504)$医药B类股多数上涨，三叶草生物涨超24%，$百奥赛图(02315)$涨超12%，$永泰(W05.SI)$生物涨超4%，嘉和生物、基石药业涨超3%。","market":"us","thumbnail":"https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"0a99b1e18c4822154f3bfeba48a50eec","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02315","150131","02197","BK1161"],"gpt_icon":0},{"id":"2567626761","title":"港股異動 | 百奧賽圖-B(02315)漲超10% 與默克簽署抗體選擇權評估協議 推進抗體偶聯脂質遞送解決方案","url":"https://stock-news.laohu8.com/highlight/detail?id=2567626761","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2567626761?lang=zh_tw&edition=fundamental","pubTime":"2025-09-15 11:03","pubTimestamp":1757905415,"startTime":"0","endTime":"0","summary":"消息面上，近日，据百奥赛图官微消息，公司与全球领先的科技公司默克已签署一项抗体选择权的评估协议，推进开发应用于核酸药物的抗体偶联脂质递送解决方案，例如抗体偶联脂质纳米颗粒。根据协议条款，百奥赛图将提供基于其RenMice平台自主开发的全人抗体，由默克评估将其用于抗体偶联LNP制剂服务的可行性。默克被授予获取选中抗体资产权益的独家选择权，百奥赛图有权获得相应的费用付款及销售分成和再许可分成。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1345095.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IE00BSNM7G36.USD","LU1066051811.HKD","LU1291159041.SGD","LU0122379950.USD","BK4533","LU1929549753.HKD","LU1983299246.USD","LU2106854487.HKD","BK4585","LU1917777945.USD","LU1934455194.USD","LU2112291526.USD","BK4559","LU1162221912.USD","LU1989771016.USD","SG9999002232.USD","LU1037948541.HKD","LU0861579265.USD","LU1061106388.HKD","LU0965509283.SGD","IE00B1BXHZ80.USD","IE00BBT3K403.USD","LU0266013472.USD","LU0320765646.SGD","LU1093756168.USD","LU1934455863.HKD","LU1941712264.USD","LU2461242641.AUD","IE00BLSP4239.USD","SG9999013999.USD","LU1941712348.USD","LU1066053197.SGD","LU1989772923.USD","LU1989772840.SGD","SG9999002224.SGD","LU1023059063.AUD","BK4007","BK4550","MRK","LU0965508806.USD","LU1571399168.USD","BK4534","LU0320765489.SGD","02315","IE00BLSP4452.SGD","IE00BFTCPJ56.SGD","LU0203345920.USD","SGXZ57979304.SGD","IE0002141913.USD","LU0070302665.USD"],"gpt_icon":0},{"id":"2566716689","title":"百奧賽圖-B09月12日主力淨流出95.2萬元 散户資金買入","url":"https://stock-news.laohu8.com/highlight/detail?id=2566716689","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2566716689?lang=zh_tw&edition=fundamental","pubTime":"2025-09-12 16:15","pubTimestamp":1757664935,"startTime":"0","endTime":"0","summary":"09月12日, 百奥赛图-B股价跌6.88%，报收23.00元，成交金额1905.5万元，换手率0.75%，振幅8.91%，量比0.98。百奥赛图-B今日主力资金净流出95.2万元，上一交易日主力净流出0万元。该股近5个交易日下跌7.67%，主力资金累计净流入255.3万元；近20日主力资金累计净流出49.1万元，其中净流出天数为9日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025091216181995281a26&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025091216181995281a26&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","02315"],"gpt_icon":0},{"id":"2566914688","title":"百奧賽圖-B盤中異動 早盤股價大跌7.13%","url":"https://stock-news.laohu8.com/highlight/detail?id=2566914688","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2566914688?lang=zh_tw&edition=fundamental","pubTime":"2025-09-11 09:31","pubTimestamp":1757554316,"startTime":"0","endTime":"0","summary":"2025年09月11日早盘09时31分，百奥赛图-B股票出现波动，股价快速跳水7.13%。截至发稿，该股报23.960港元/股，成交量1.75万股，换手率0.02%，振幅7.60%。百奥赛图-B股票所在的生物技术行业中，整体跌幅为10.03%。百奥赛图-B公司简介：北京百奥赛图基因生物技术有限公司是一家主要从事药物开发业务及临床前研究中国公司。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202509110931569523612a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202509110931569523612a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","02315"],"gpt_icon":0},{"id":"2566263524","title":"百奧賽圖-B09月08日主力淨流入187.2萬元 散户資金拋售","url":"https://stock-news.laohu8.com/highlight/detail?id=2566263524","media":"市场透视","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2566263524?lang=zh_tw&edition=fundamental","pubTime":"2025-09-08 16:15","pubTimestamp":1757319358,"startTime":"0","endTime":"0","summary":"09月08日, 百奥赛图-B股价涨3.28%，报收25.84元，成交金额3899.8万元，换手率1.37%，振幅6.39%，量比3.30。百奥赛图-B今日主力资金净流入187.2万元，上一交易日主力净流出33.0万元。该股近5个交易日上涨3.36%，主力资金累计净流入35.6万元；近20日主力资金累计净流出104.7万元，其中净流出天数为8日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250908170730a4bacb34&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250908170730a4bacb34&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","02315"],"gpt_icon":0},{"id":"1187418735","title":"百奧賽圖與Merck達成合作協議，共同推進抗體偶聯脂質遞送解決方案","url":"https://stock-news.laohu8.com/highlight/detail?id=1187418735","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1187418735?lang=zh_tw&edition=fundamental","pubTime":"2025-09-04 08:01","pubTimestamp":1756944115,"startTime":"0","endTime":"0","summary":"百奥赛图与Merck达成合作协议，共同推进抗体偶联脂质递送解决方案","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02315","BK1161"],"gpt_icon":0},{"id":"2564343327","title":"百奧賽圖與默克簽署協議，推進抗體偶聯脂質遞送解決方案","url":"https://stock-news.laohu8.com/highlight/detail?id=2564343327","media":"美通社","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2564343327?lang=zh_tw&edition=fundamental","pubTime":"2025-09-04 08:00","pubTimestamp":1756944000,"startTime":"0","endTime":"0","summary":"根据协议条款，百奥赛图将提供基于其RenMice平台自主开发的全人抗体，由默克评估将其用于抗体偶联LNP制剂服务的可行性。百奥赛图董事长及CEO沈月雷博士表示：\"我们很高兴再次与默克携手，探索抗体偶联脂质递送系统的潜力。我们希望通过百奥赛图在抗体发现方面的专业能力，结合默克在LNP领域的深厚积累，加速下一代核酸递送解决方案的开发。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://wwwold.prnasia.com/story/archive/4764438_ZH64438_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["LU1066051811.HKD","SG9999002224.SGD","SG9999002232.USD","LU1585245621.USD","LU1066051498.USD","BK4588","SG9999014567.USD","LU1023059063.AUD","LU1061106388.HKD","LU1116320901.HKD","LU2106854487.HKD","LU2023250843.SGD","LU1093756168.USD","LU1929549753.HKD","LU2089984988.USD","LU1934455194.USD","IE00B1BXHZ80.USD","LU0106261372.USD","LU0266013472.USD","SG9999015341.SGD","LU0203345920.USD","IE00BLSP4452.SGD","LU1291159041.SGD","LU0208291251.USD","LU1057294990.SGD","LU1941712264.USD","BK4585","LU1116320737.USD","LU1066053197.SGD","LU1035773651.USD","LU1162221912.USD","LU0965509283.SGD","BK4007","LU0320765489.SGD","SG9999014559.SGD","SG9999015358.SGD","LU0320765646.SGD","LU0234572021.USD","BK4533","BK1161","LU2461242641.AUD","SG9999014542.SGD","SG9999014575.USD","LU2361044865.SGD","MRK","IE0009355771.USD","LU2361045086.USD","LU0238689110.USD","02315","IE00BN8TJ469.HKD"],"gpt_icon":0}],"pageSize":20,"totalPage":8,"pageCount":3,"totalSize":153,"code":"91000000","status":"200"}]}}